Cognitive impairment could potentially be screened for in people with multiple sclerosis (MS) using optical coherence tomography (OCT) to measure retinal layer thickness (RLT), identifying high-risk patients for further neuropsychological testing.
Why this matters
Cognitive impairment can be a significant feature of MS, even for people with early-stage disease. It is difficult to identify early, with regular neuropsychological monitoring for cognitive impairment not well integrated into the current model of care.
Measuring RLT using OCT is an inexpensive and feasible tool that has been used in MS to measure neurodegeneration. It is possible RLT could be a biomarker of cognitive impairment.